MedPath

Ketorolac

Generic Name
Ketorolac
Brand Names
Acular, Acuvail, Omidria, Readysharp Anesthetics Plus Ketorolac, Sprix, Toradol, Toronova Suik
Drug Type
Small Molecule
Chemical Formula
C15H13NO3
CAS Number
74103-06-3
Unique Ingredient Identifier
YZI5105V0L
Background

Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution.

It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent.

Indication

Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and has antipyretic, analgesic and anti-inflammatory properties. It is indicated for short term management of acute pain that requires the calibre of pain management offered by opioids. Clinicians may choose to initiate ketorolac to manage post-operative pain, spinal and soft tissue pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders and headaches among other ailments. Regardless of the etiology of pain, patients should use the lowest possible dose, and avoid using ketorolac for an extended period of time (ideally ≤ 5 days). A benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac use.

Associated Conditions
Acute Migraine, Eye Pain, Inflammation, Macular Edema, Cystoid, Ocular Itching, Pericarditis Acute, Pseudophakic Cystoid Macular Oedema, Severe Acute Pain, Acute, moderate Pain, Chronic aphakic cystoid macular edema, Intraoperative miosis, Postoperative ocular pain
Associated Therapies
-

Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy

Phase 4
Completed
Conditions
Renal Calculus
Kidney Stones
Interventions
Drug: Placebo
Drug: Ketorolac
First Posted Date
2008-10-02
Last Posted Date
2012-01-27
Lead Sponsor
Mayo Clinic
Target Recruit Count
17
Registration Number
NCT00765128
Locations
🇺🇸

Mayo Clinic, Phoenix, Arizona, United States

Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy

Phase 4
Completed
Conditions
Nephrectomy
Laparoscopic Donor Nephrectomy
Interventions
Drug: Placebo
Drug: Ketorolac
First Posted Date
2008-10-02
Last Posted Date
2012-01-27
Lead Sponsor
Mayo Clinic
Target Recruit Count
111
Registration Number
NCT00765232
Locations
🇺🇸

Mayo Clinic, Phoenix, Arizona, United States

Effect of Spinal Ketorolac After Acute Opioid Exposure

Phase 2
Terminated
Conditions
Healthy
Interventions
First Posted Date
2008-06-06
Last Posted Date
2018-09-07
Lead Sponsor
Wake Forest University
Target Recruit Count
30
Registration Number
NCT00693160
Locations
🇺🇸

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management

Phase 4
Completed
Conditions
Postoperative Pain
Interventions
First Posted Date
2008-03-19
Last Posted Date
2018-08-07
Lead Sponsor
Maimonides Medical Center
Target Recruit Count
67
Registration Number
NCT00638508
Locations
🇺🇸

Maimonides Medical Center, Brooklyn, New York, United States

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

Phase 4
Terminated
Conditions
Blindness
Retinopathy of Prematurity
Retinal Detachment
Interventions
Drug: placebo
Drug: ACULAR
Drug: REFRESH TEARS
First Posted Date
2008-03-13
Last Posted Date
2020-12-08
Lead Sponsor
University of South Alabama
Target Recruit Count
83
Registration Number
NCT00634972
Locations
🇺🇸

Division of Neonatology, Children's & Women's Hospital, University of South Alabama, Mobile, Alabama, United States

Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

Phase 4
Completed
Conditions
Acute Pseudophakic Cystoid Macular Edema
Interventions
First Posted Date
2008-01-16
Last Posted Date
2009-03-19
Lead Sponsor
Bp Consulting, Inc
Target Recruit Count
166
Registration Number
NCT00595543
Locations
🇺🇸

Soll Eye Associates, Philadelphia, Pennsylvania, United States

Topical 0.4% Ketorolac and Vitreoretinal Surgery

Phase 2
Completed
Conditions
Surgery
Interventions
First Posted Date
2007-12-19
Last Posted Date
2014-05-14
Lead Sponsor
Emory University
Target Recruit Count
76
Registration Number
NCT00576329
Locations
🇺🇸

Emory Eye Clinic, Atlanta, Georgia, United States

Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty

Phase 4
Completed
Conditions
Osteoarthritis of the Knee
Interventions
First Posted Date
2007-11-22
Last Posted Date
2011-08-08
Lead Sponsor
Asker & Baerum Hospital
Target Recruit Count
102
Registration Number
NCT00562627
Locations
🇳🇴

Asker and Baerum Hospital, Rud, Norway

RCT on Ketorolac and Tramadol in Bone Fractures Pain of Child

Phase 4
Completed
Conditions
Fracture
Pain
Interventions
First Posted Date
2007-11-19
Last Posted Date
2017-08-24
Lead Sponsor
IRCCS Burlo Garofolo
Target Recruit Count
133
Registration Number
NCT00560443
Locations
🇮🇹

IRCCS Burlo Garofolo, Trieste, Italy

Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers

First Posted Date
2007-10-24
Last Posted Date
2008-07-16
Lead Sponsor
Javelin Pharmaceuticals
Target Recruit Count
30
Registration Number
NCT00548678
Locations
🇺🇸

Comprehensive Phase One, Miramar, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath